Thyroid testing during pregnancy at an academic Boston Area Medical Center

Gestational hypothyroidism leads to adverse obstetric outcomes and intellectual impairment in offspring. Pregnancy thyroid screening is controversial.

Our objective was to determine thyroid function testing and thyroid dysfunction rates in pregnant women at Boston Medical Center (BMC).

We retrospectively enrolled 1000 pregnant women aged 18-46 yr seen in BMC's Obstetrics/Gynecology (OB/GYN) or Family Medicine (FM) Clinics for their initial prenatal visit during 2008. Age, race, insurance, gestational age (GA), medical history (thyroid or other autoimmune disorders), obstetric history, and thyroid function tests were ascertained.

A total of 983 women were included (17 excluded for coding error). Median maternal age was 28 yr and GA 9.4 wk. Thyroid testing rates were similar in the 918 (93%) followed by OB/GYN and 65 (7%) followed by FM (84 vs. 86%). Thirty-nine women had previous thyroid disease, of whom 19 took thyroid medications. Four had type 1 diabetes, and nine had other autoimmune diseases. Serum TSH was obtained in 832 women (84.6%) at median GA 9.7 wk (range, 0.1-39.7). The majority were tested during their first trimester (65.5%). Of the 832 tested, 56 (6.7%) had trimester-specific elevated TSH, of whom nine had a previous history of thyroid disease, two had type 1 diabetes, and one had dyschromia. Based on current case-finding guidelines, 45 of 56 women (80.4%) with an elevated TSH in pregnancy might not have been tested.

BMC has a high rate of thyroid function testing in pregnancy. Targeted thyroid testing in only high-risk patients would have missed 80.4% of pregnant women with hypothyroidism.